476342-37-7

Basic information

• Product Name: 1-(5-Amino-2-pyridinyl)-4-piperidinol
• Synonyms: 1-(5-Amino-2-pyridinyl)-4-piperidinol
• CAS NO: 476342-37-7
• Molecular Formula: C₁₀H₁₅N₃O
• Molecular Weight: 193.25
• Product Categories: pharmacetical
• Mol File: 476342-37-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 448.8°Cat760mmHg
• Flash Point: 225.3°C
• Appearance: /
• Density: 1.253g/cm³
• Vapor Pressure: 7.67E-09mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 14.73±0.20(Predicted)
• CAS DataBase Reference: 1-(5-Amino-2-pyridinyl)-4-piperidinol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-Amino-2-pyridinyl)-4-piperidinol(476342-37-7)
• EPA Substance Registry System: 1-(5-Amino-2-pyridinyl)-4-piperidinol(476342-37-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 476342-37-7(Hazardous Substances Data)

Usage

General Description

1-(5-Amino-2-pyridinyl)-4-piperidinol is a chemical compound with the molecular formula C11H16N2O. It is a piperidine derivative that contains a pyridine ring with an amino group attached to the 5-position. 1-(5-Amino-2-pyridinyl)-4-piperidinol has potential pharmaceutical applications due to its structure and properties, and it may act as a precursor or intermediate in organic synthesis. Its exact uses and potential effects are subject to further research and evaluation.

InChI:InChI=1/C10H15N3O/c11-8-1-2-10(12-7-8)13-5-3-9(14)4-6-13/h1-2,7,9,14H,3-6,11H2

Upstream product

• 353258-16-9 1-(5-nitropyridin-2-yl)piperidin-4-ol 

Downstream Products

• 1221420-36-5 4-(4-chlorophenyl)-1-((dimethylamino)methyleneamino)-N-(6-(4-hydroxypiperidin-1-yl)pyridin-3-yl)-1H-pyrrole-2-carboxamide 

Relevant articles and documents

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Diacylglycerol acyltransferase inhibitors

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.